Trastuzumab

Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to HER2 with high affinity. Trastuzumab can be used for the research of HER2-positive metastatic breast cancer and gastric cancer[1][2][3]. (Note: The product specifications below only indicate the effective content of Trastuzumab. The component ratio of this product is Trastuzumab : excipients = 1:0.6-1:0.9.)

Product Specifications

CAS Number

[180288-69-1]

Product Name Alternative

Anti-Human HER2, Humanized Antibody

UNSPSC

12352203

Hazard Statement

H302, H315, H319, H335

Target

ADC Antibody; EGFR; Radionuclide-Drug Conjugates (RDCs)

Type

Inhibitory Antibodies

Related Pathways

Antibody-drug Conjugate/ADC Related; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Trastuzumab.html

Purity

99.80

Solubility

H2O

Smiles

[Trastuzumab]

Molecular Weight

(145.36 kDa)

Precautions

H302, H315, H319, H335

References & Citations

[1]Sliwkowski MX, et al. Nonclinical studies addressing the mechanism of action of trastuzumab. Semin Oncol. 1999 Aug;26 (4 Suppl 12) :60-70.|[2]Hudis CA, et al. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med. 2007 Jul 5;357 (1) :39-51.|[3]Barok M, et al. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther. 2007 Jul;6 (7) :2065-72.